Biocon tranquilize gets DCGI gesture for use in moderate to extreme COVID-19 patients Kumar Jeetendra | July 11, 2020 DCGI has vowed to market Itolizumab (ALZUMAb) injection 25mg and 5mL solution for emergency usage within India for the cure of cytokine release syndrome (CRS) at moderate to severe ARDS (acute respiratory distress syndrome) patients thanks to COVID-19, Biocon said in a release. It said Itolizumab is your first publication biologic therapy to become approved …
Gilead says Extra data on remdesivir Reveals improved clinical Retrieval Kumar Jeetendra | July 10, 2020 Gilead Sciences Inc said on Friday additional data from a late-stage study revealed its antibacterial remdesivir significantly enhanced clinical recovery from seriously ill COVID-19 patients. Findings from a study of its late-stage study revealed that 74.4 percent of remdesivir-treated patients recovered by Day 14 versus 59.0 percentage of individuals receiving standard of care, the business …
Research center testing affirms adequacy of BETADINE germicide items against SARS-CoV-2 Kumar Jeetendra | July 10, 2020 Mundipharma today announced that lab testing at the Duke NUS Medical School at Singapore, has confirmed the potency of its BETADINE® antiseptic services and products against the publication coronavirus (SARS-CoV-2) that causes COVID-19 disease. Testing has demonstrated BETADINE’s® strong in vitro virucidal exercise, killing 99.99% of the SARS-CoV-2 virus in 30 seconds. The investigation was …
Strides Pharma gains on USFDA endorsement Kumar Jeetendra | July 9, 2020 Strides Pharma Science climbed 1.28percent to R S 416.60 as a result of its Singapore-based subsidiary, Strides Pharma Global, received US FDA approval for butalbital, acetaminophen, caffeine, and codeine phosphate capsules. According to IQVIA MAT May 2020 statistics, the US market for butalbital, acetaminophen, caffeine, and codeine phosphate capsules, and 50 mg/325 mg/40 mg/30 mg, …
COVID-19 immunization: Premas Biotech starts mice examines Kumar Jeetendra | July 9, 2020 Premas Biotech, the Gurgaon-based Biotech organization which built up the triple antigen infection like molecule (VLP) immunization contender for SARS CoV-2 infection, said it had advanced into creature preliminaries. “The four-week fake treatment controlled, blinded and randomized tests to be directed in mice, will look to assess security in the rat display and analyze insusceptible …
Cipla dispatches nonexclusive rendition of remdesivir in India Kumar Jeetendra | July 9, 2020 Pharma important Cipla on Wednesday said it has launched its own generic version of antiviral drug remdesivir at a cost which is one of the lowest internationally and is seeking to supply over 80,000 vials over the first month. The company, however, did not disclose the purchase price of the medicine. Cipla had earlier said …
Unichem Laboratories gets USFDA gesture for Cyclobenzaprine HCI Tablets Kumar Jeetendra | July 8, 2020 Unichem Laboratories has gotten ANDA endorsement for its Cyclobenzaprine Hydrochloride Tablets USP, 5 mg, 7.5 mg and 10 mg from the United States Food and Drug Administration (USFDA) to showcase a nonexclusive rendition of FLEXERIL (Cyclobenzaprine HCI) Tablets, 5 mg and 10 mg of Janssen Research and Development LLC. Cyclobenzaprine HCI Tablets are shown for …
Baxter India gets CDSCO gesture for utilization of its Oxiris channel in COVID-19 treatment Kumar Jeetendra | July 7, 2020 Healthcare firm Baxter India on Tuesday said it has received consent from the Central Drugs Standard Control Organisation (CDSCO) for the usage of its Oxiris blood purification filter to the treatment of COVID-19 patients. The filter is meant to be utilised in the seriously ill COVID-19 patients needing blood purification where excess inflammatory mediators are …
China’s Sinovac begins late stage preliminaries for its COVID-19 antibody Kumar Jeetendra | July 7, 2020 China’s Sinovac Biotech is starting Phase III trials of its potential coronavirus vaccine in Brazil, ” said on Monday, becoming among three companies to transfer to the late stages at the race to develop an inoculation against the disorder. It follows a fast-track approval for the trials by Brazilian labs last week. Sinovac stated the …
Mylan’s remdesivir will be available to patients in India at July at Rs.4,800 Kumar Jeetendra | July 6, 2020 Drugmaker Mylan NV said on Monday it secured approval to establish its generic model of Gilead Sciences Inc’s Covid-19 therapy medication remdesivir in India this month at $4,800 per 100 mg vial, as illnesses surge on earth’s third worst-hit country by herpes. The Drug Controller General of India (DCGI) accepted Mylan’s remdesivir model, to be …
CCRS to Start study on prophylactic use of Siddha in treating COVID-19 cases Kumar Jeetendra | June 29, 2020 Chennai, June 29 (PTI) Using a Siddha”addition” treatment to allopathic therapy in a government COVID-19 care facility giving encouraging results, the Central Council for Research at Siddha (CCRS) will shortly start a research on 60 coronavirus patients in Vysarpadi in town. The new clinical trial aims to bring the effectiveness of this Siddha group of …
Cipla and Boehringer Ingelheim forge partnership to co-market three oral anti-diabetic drugs Kumar Jeetendra | June 29, 2020 Mumbai, June 29, 2020 : Cipla Limited (BSE: 500087; NSE: CIPLA EQ; hereafter referred to as “Cipla”) and Boehringer Ingelheim India Pvt. Ltd. (BI) today announced their partnership in India to co-market three new oral anti-diabetics drugs Oboravo® (Empagliflozin), Oboravo Met® (Empagliflozin+Metformin) and Tiptengio® (Empagliflozin+Linagliptin) Empagliflozin is approved for glucose-control in patients with type-2 diabetes; …
